Genor Biopharma Snares $160M in Series B Financing Round

According to sensorexpert.com, Genor Biopharma Co. Ltd. ("Genor") has closed a $160 million Series B round, led by existing shareholder Hillhouse Capital, with participation from new investors including Temasek, CR CP Life Sciences Fund, Haitong Capital International and Cavenham PE.

Proceeds from the latest round will be used to advance clinical projects in existing product pipelines, do research and development of innovative drugs in early-stage, establish strategic cooperation at home and abroad, and to prepare for the commercialization of products currently in the late stage of R&D.

Genor is a science-driven, innovative biologics powerhouse founded in December 2007, with a focus on bringing affordable therapeutics to patients. Currently, Genor has more than ten products in the pipeline, and ten of them have entered into clinical development.

Under the leadership of a management team with more than 20 years of experience in global biopharmaceutical companies such as Roche, Amgen, and AbbVie, Genor currently has over 400 employees across 3 sites in China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as our lab in South San Francisco, US, among which more than 80% are R&D specialists.

"2020 is a crucial year for Genor," said Dr. Guo Feng, CEO of Genor. "We are putting the finishing touches on listing applications for some late-stage products and accelerating the development of innovative drugs for tumor immunotherapy."

Hillhouse is a long-term fundamental equity investor. The company owns companies across equity stages, spanning the range from new start-ups to the world’s most established public companies. It invests globally, with a particular focus on Asia. The team members of the company are sector experts in consumer, Internet, media, and healthcare.

Temasek is an investment company with a net portfolio value of US$313 billion (RMB1.55t) as of 31 March 2019. Its investment philosophy is anchored around four key themes: Transforming Economies; Growing Middle-Income Populations; Deepening Comparative Advantages; and Emerging Champions. Headquartered in Singapore, the company has 11 offices around the world.